Tocilizumab

Individualized care and patient satisfaction are among the areas of emphasis in a new consensus statement on management of thyroid eye disease.

The FDA has accepted an abbreviated biologics license application for a tocilizumab biosimilar candidate, according to a press release from Biogen.

NASHVILLE, Tenn. — Combination therapy with remdesivir and dexamethasone plus tocilizumab yielded reductions in inflammatory markers and mortality and more discharges for patients with COVID-19 hospitalized in the ICU, researchers reported.

The FDA has granted priority review for intravenous tocilizumab to treat adults hospitalized with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation.

A subset of patients with Still’s disease develop drug reactions with eosinophilia and systemic symptoms to interleukin-1 and IL-6 inhibitors, with strong associations among those with common HLA-DRB1*15 haplotypes, according to data.

Weekly tocilizumab delays initial flare and reduces glucocorticoid exposure in patients with relapsing and new-onset giant cell arteritis, according to data published in Rheumatology.

Treatment for thyroid eye disease should be personalized, with joint input from endocrinologists and ophthalmologists, according to two speakers.

First-line treatment of thyroid eye disease differs around the globe, with teprotumumab the most commonly prescribed treatment in North America and IV steroids most common in Europe, according to a speaker.

Tocilizumab plus glucocorticoids is beneficial for patients with COVID-19 who require oxygen therapy, according to updated EULAR “points to consider” on the use of immunomodulatory therapies in SARS-CoV-2.

In a disturbing repeat of last year’s run on hydroxychloroquine, U.S. health care systems are scrambling to maintain tocilizumab access for rheumatology patients following the drug’s emergency use authorization for COVID-19 and the surge in delta variant cases.